Salvage Therapy of Multiple Myeloma: The New Generation Drugs | Zendy

Alessandra Romano | Zendy; Concetta Conticello | Zendy; Maide Cavalli | Zendy; Calogero Vetro | Zendy; Cosimo Di Raimondo | Zendy; Valentina Martina | Zendy; Elena Schinocca | Zendy; Alessia La Fauci | Zendy; Nunziatina Laura Parrinello | Zendy; Annalisa Chiarenza | Zendy; Francesco Di Raimondo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Salvage Therapy of Multiple Myeloma: The New Generation Drugs

Author(s) -

Alessandra Romano,

Concetta Conticello,

Maide Cavalli,

Calogero Vetro,

Cosimo Di Raimondo,

Valentina Martina,

Elena Schinocca,

Alessia La Fauci,

Nunziatina Laura Parrinello,

Annalisa Chiarenza,

Francesco Di Raimondo

Publication year - 2014

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2014/456037

Subject(s) - bendamustine , medicine , salvage therapy , multiple myeloma , disease , clinical trial , oncology , antibody therapy , proteasome inhibitor , refractory (planetary science) , proteasome , bortezomib , pharmacology , monoclonal antibody , bioinformatics , intensive care medicine , immunology , antibody , chemotherapy , rituximab , biology , astrobiology , microbiology and biotechnology

During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and new drugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MM as emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research